Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy
dc.contributor.author | Apellániz Ruiz, María | |
dc.contributor.author | Tejero Franco, Héctor | |
dc.contributor.author | Inglada Pérez, Lucía Silvia | |
dc.contributor.author | Sánchez Barroso, Lara | |
dc.contributor.author | Gutiérrez Gutiérrez, Gerardo | |
dc.contributor.author | Calvo, Isabel | |
dc.contributor.author | Castelo, Beatriz | |
dc.contributor.author | Redondo, Andrés | |
dc.contributor.author | García Donás, Jesús | |
dc.contributor.author | Romero Laorden, Nuria | |
dc.contributor.author | Sereno, María | |
dc.contributor.author | Merino, María | |
dc.contributor.author | Currás Freixes, María | |
dc.contributor.author | Montero Conde, Cristina | |
dc.contributor.author | Mancikova, Veronika | |
dc.contributor.author | Åvall Lundqvist, Elisabeth | |
dc.contributor.author | Green, Henrik | |
dc.contributor.author | Al-Shahrour, Fátima | |
dc.contributor.author | Cascón, Alberto | |
dc.contributor.author | Robledo, Mercedes | |
dc.contributor.author | Rodríguez Antona, Cristina | |
dc.date.accessioned | 2024-01-29T15:41:04Z | |
dc.date.available | 2024-01-29T15:41:04Z | |
dc.date.issued | 2017 | |
dc.description.abstract | Purpose: Neuropathy is the dose-limiting toxicity of paclitaxel and a major cause for decreased quality of life. Genetic factors have been shown to contribute to paclitaxel neuropathy susceptibility; however, the major causes for interindividual differences remain unexplained. In this study, we identified genetic markers associated with paclitaxel-induced neuropathy through massive sequencing of candidate genes. Experimental Design: We sequenced the coding region of 4 EPHA genes, 5 genes involved in paclitaxel pharmacokinetics, and 30 Charcot–Marie–Tooth genes, in 228 cancer patients with no/low neuropathy or high-grade neuropathy during paclitaxel treatment. An independent validation series included 202 paclitaxel-treated patients. Variation-/gene-based analyses were used to compare variant frequencies among neuropathy groups, and Cox regression models were used to analyze neuropathy along treatment. Results: Gene-based analysis identified EPHA6 as the gene most significantly associated with paclitaxel-induced neuropathy. Low-frequency nonsynonymous variants in EPHA6 were present exclusively in patients with high neuropathy, and all affected the ligand-binding domain of the protein. Accumulated dose analysis in the discovery series showed a significantly higher neuropathy risk for EPHA5/6/8 low-frequency nonsynonymous variant carriers [HR, 14.60; 95% confidence interval (CI), 2.33–91.62; P ¼ 0.0042], and an independent cohort confirmed an increased neuropathy risk (HR, 2.07; 95% CI, 1.14–3.77; P ¼ 0.017). Combining the series gave an estimated 2.5-fold higher risk of neuropathy (95% CI, 1.46–4.31; P ¼ 9.1 10 4). Conclusions: This first study sequencing EPHA genes revealed that low-frequency variants in EPHA6, EPHA5, and EPHA8 contribute to the susceptibility to paclitaxel-induced neuropathy. Furthermore, EPHA's neuronal injury repair function suggests that these genes might constitute important neuropathy markers for many neurotoxic drugs. | |
dc.description.department | Depto. de Enfermería | |
dc.description.faculty | Fac. de Enfermería, Fisioterapia y Podología | |
dc.description.refereed | TRUE | |
dc.description.status | pub | |
dc.identifier.citation | María Apellániz-Ruiz, Héctor Tejero, Lucía Inglada-Pérez, Lara Sánchez-Barroso, Gerardo Gutiérrez-Gutiérrez, Isabel Calvo, Beatriz Castelo, Andrés Redondo, Jesús García-Donás, Nuria Romero-Laorden, María Sereno, María Merino, María Currás-Freixes, Cristina Montero-Conde, Veronika Mancikova, Elisabeth Åvall-Lundqvist, Henrik Green, Fátima Al-Shahrour, Alberto Cascón, Mercedes Robledo, Cristina Rodríguez-Antona; Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy. Clin Cancer Res 1 March 2017; 23 (5): 1227–1235. https://doi.org/10.1158/1078-0432.CCR-16-0694 | |
dc.identifier.doi | 10.1158/1078-0432.ccr-16-0694 | |
dc.identifier.essn | 1557-3265 | |
dc.identifier.issn | 1078-0432 | |
dc.identifier.officialurl | https://doi.org/10.1158/1078-0432.CCR-16-0694 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14352/96185 | |
dc.issue.number | 5 | |
dc.journal.title | Clinical Cancer Research | |
dc.language.iso | eng | |
dc.page.final | 1235 | |
dc.page.initial | 1227 | |
dc.rights.accessRights | open access | |
dc.subject.cdu | 61 | |
dc.subject.cdu | 575:61 | |
dc.subject.keyword | EPHA genes | |
dc.subject.keyword | Paclitaxel | |
dc.subject.keyword | Peripheral neuropathy | |
dc.subject.ucm | Ciencias Biomédicas | |
dc.subject.ucm | Genética médica | |
dc.subject.unesco | 24 Ciencias de la Vida | |
dc.title | Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy | |
dc.type | journal article | |
dc.type.hasVersion | AM | |
dc.volume.number | 23 | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | 18889f7c-d57c-4837-a726-3a5d71756d3d | |
relation.isAuthorOfPublication | 4d11dbbf-1deb-40c5-bc98-c9271b13cf39 | |
relation.isAuthorOfPublication | 656421b3-1a98-4c54-8f7a-6ac32e278bbb | |
relation.isAuthorOfPublication.latestForDiscovery | 4d11dbbf-1deb-40c5-bc98-c9271b13cf39 |